Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: The phase III PROOF 302 trial

Sumanta K. Pal, Diederik M. Somford, Petros Grivas, Srikala S. Sridhar, Shilpa Gupta, Joaquim Bellmunt, Guru Sonpavde, Mark T. Fleming, Seth P. Lerner, Yohann Loriot, Jean Hoffman-Censits, Begoña P. Valderrama, Corina Andresen, Marco J. Schnabel, Suzanne Cole, Siamak Daneshmand

Research output: Contribution to journal › Article › peer-review